Pharmacogenetics - Where are we and where are we heading?

Pharmacogenomics

Volumn 6, Issue 8, 2005, Pages 793-795

  Kola, Ismail ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; AZATHIOPRINE; BEVACIZUMAB; CETUXIMAB; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PERHEXILINE; PHENYTOIN; ROFECOXIB; THIOPURINE METHYLTRANSFERASE; TRASTUZUMAB;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL INFECTION; BREAST CANCER; CANCER SURVIVAL; COLON CANCER; COST BENEFIT ANALYSIS; COST CONTROL; DOSE RESPONSE; DRUG ABSORPTION; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG METABOLISM; DRUG SAFETY; EDITORIAL; ENZYME ACTIVITY; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENOTYPE; HUMAN; NEUROPATHY; PHARMACODYNAMICS; PHARMACOGENETICS; REGISTRATION; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

DRUG INDUSTRY; PHARMACOGENETICS; PHARMACOKINETICS;

BACTERIA (MICROORGANISMS);

EID: 28444476614     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.6.8.793     Document Type: Editorial

References (7)

1. Kola I, Landis J: Can the pharmaceutical industry reduce attrition rates? Nature Rev. Drug Discov. 3(8), 711-715 (2004).
2. Kola I, Hazuda D: Innovation and greater probability of success in drug discovery and development - from target to biomarkers. Curr. Opin. Biotechnol. (Epub ahead of print) (2005).
3. Marshall A: Laying the foundations for personalized medicines. Nature Biotech. 15, 954-957 (1997).
4. Goldstein D: Pharmacogenetics, pharmacogenomics and proteomics - applications is biomedicine and human health. Presentation at OECD Conference on Pharmacogenetics and Drug Research, Rome, Italy (2005).
5. Shah R: Enhancing the benefit to risk ratio of new pharmaceuticals with pharmacogenetic approaches: using genomic biomarkers to influence efficacy or safety. Presentation at OECD Conference on Pharmacogenetics and Drug Research, Rome, Italy (2005).
6. Weinshilboum RM, Otterness DM, Szumlanski CL: Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu. Rev. Pharmacol. Toxicol. 39, 19-52 (1999).
7. Berenson A: Cancer drugs offer hope, but at a huge expense. New York Times, 12 July 2005.